EUCTR2017-005006-35-GB进行中（未招募）1 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects upstream of the MC4 receptor in the leptin-melanocortinpathway
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1. Patients aged 6 or older that have completed participation on active drug and demonstrated adequate safety and meaningful clinical benefit (efficacy) in a previous setmelanotide study for obesity associated with genetic defects upstream of the MC4
- •receptor in the leptin-melanocortin pathway.
- •Note: The index study may have a primary endpoint relied on efficacy, safety or tolerability. Patient will be eligible for extension study if the Primary Investigator believes the patient exhibited a clinically meaningful benefit (i,e, efficacy) to setmelanotide treatment, and would benefit from continued treatment, after discussion with the Sponsor.
- •2. Study participant and/or parent or guardian is able to communicate well with the investigator, to understand and comply with the requirements of the study, and to understand and sign the written informed consent/assent.
- •The patient must assent/consent to participate in the trial.
- •3. Female participants of child-bearing potential must agree to use contraception as outlined in the protocol. Female participants of non-childbearing potential, defined as surgically sterile (status post hysterectomy, bilateral oophorectomy, or bilateral tubal ligation), postmenopausal for at least 12 months (and confirmed with a
- •screening FSH level in the post-menopausal lab range), or have delayed pubertal development and failure to have achieved menarche, do not require contraception during the study. Any female participant in this latter category of having failed to reach menarche upon study entry, that suspects this status may have changed should promptly inform the investigator and undergo pregnancy testing. If confirmed to be of child bearing potential, the participant must agree to use contraception as outlined in the protocol. Male participants with female partners of childbearing potential must agree to a double barrier method if they become sexually active during the study.
- •Male patients must not donate sperm during and for 90 days following their participation in the study.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 150
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 67
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •ALL Patients:
- •1.Pregnant and/or breastfeeding women
- •2.Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion), determined as part of a screening comprehensive skin evaluation performed by a qualified dermatologist. Any concerning lesions identified during the screening period will be biopsied and results known to be benign prior to enrollment. If the pre-treatment biopsy results are of concern, the patient may need to be excluded from the study.
- •3. Patient is, in the opinion of the Study Investigator, not suitable to participate in the study.
- •In addition, any patient who experiences a gap in treatment of at least one month between completing the Index study and Screening for this study, should have the following exclusion criteria evaluated:
- •4. Current, clinically significant disease, if severe enough to interfere with the study and/or would confound the results. Any such patients should be discussed with the Sponsor prior to inclusion
- •5. Diagnosis of schizophrenia, bipolar disorder, personality disorder or other Diagnostic and Statistical Manual of Mental Disorders (DSM-III) disorders that the investigator believes will interfere significantly with study compliance.
- •6. A Patient Health Questionnaire-9 (PHQ-9) score of = 15.
- •7. Any suicidal ideation of type 4 or 5 on the Columbia Suicide Severity Rating Scale (CSSRS). Any lifetime history of a suicide attempt, or any suicidal behavior in the last month.
- •Note: Patients who are unable to complete the PHQ-9 or C-SSRS due to significant neurocognitive defects may be enrolled in the study, as long as in the opinion of the Primary Investigator there are no clinical signs or symptoms of suicidal behavior.
- •8. History of significant liver disease or liver injury, or a current liver assessment due to abnormal liver tests (as indicated by abnormal liver function tests, alanine transaminase [ALT], aspartate transaminase [AST], alkaline phosphatase, or serum bilirubin >1.5× the upper limit of normal [ULN] for any of these tests) for an etiology other than nonalcoholic fatty liver disease (NAFLD). Thus, any underlying etiology besides NAFLD, including diagnosed non-alcoholic steatohepatitis (NASH), other causes of hepatitis, or history of hepatic cirrhosis is exclusionary, but the presence of NAFLD is not be exclusionary.
- •9. Moderate to severe renal dysfunction as defined by a glomerular filtration rate (GFR)
- •<30 mL/min.
- •10. History or close family history (parents or siblings) of skin cancer or melanoma (not including non-invasive/infiltrative basal or squamous cell lesion), or patient history of ocular-cutaneous albinism.
研究者
相似试验
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects.Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Some rare genetic disorders include:obesity, including: Leptin Receptor (LepR) Deficiency Obesity POMC Heterozygous Deficiency Obesity POMC Epigenetic Deficiency Obesity Bardet-Biedl syndromeAlström syndromeEUCTR2017-005006-35-ESRhythm Pharmaceuticals, Inc.150
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated withgenetic defects.Patients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Some rare genetic disorders include, but not limited to:obesity, including: Leptin Receptor (LepR) Deficiency Obesity POMC Heterozygous Deficiency Obesity PCSK deficiency obesity Bardet-Biedl syndromeAlström syndromeEUCTR2017-005006-35-GRRhythm Pharmaceuticals, Inc.220
招募中
3 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwaygenetic mutation10003018ObesityNL-OMON54784RHYTHM Pharmaceuticals14
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide (RM-493) for patients who have completed a trial of Setmelanotide for the treatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwayTreatment of obesity associated with genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathwayEUCTR2017-005006-35-FRRhythm Pharmaceuticals, Inc.100
进行中（未招募）
1 期
ong Term Extension Trial of setmelanotide for patients who havecompleted a trial of Setmelanotide for the treatment of obesity associated with genetic defectsPatients with obesity caused by genetic defects upstream of the MC4 receptor in the leptin-melanocortin pathway. Human Genetics studies have identified several diseases that are the result of genetic defects affecting the MC4R pathway, for example:•POMC deficiency obesity due to mutations in the POMC gene•PCSK1 deficiency due to mutations in the PCSK1 gene•LEPR deficiency obesity due to mutations in the LEPR gene•Bardet-Biedl syndrome•Alström syndromeEUCTR2017-005006-35-NLRhythm Pharmaceuticals, Inc.109